Skip to content

Comparison of the effects of remazolam and midazolam on the incidence of delirium following general anesthesia in patients undergoing elective non- cardiac major surgery: A prospective, randomized controlled study

Comparison of the effects of remimazolam and midazolam on the incidence of delirium following general anesthesia in patients undergoing elective non-cardiac major surgery: A prospective, case-control study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121519
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-02-12
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

Remi Group:Intravenous injection of Tolfenamic Acid Remimazolam 0.3mg/kg before anesthesia induction
Mida Group:Intravenous injection of Midazolam Injection 0.05mg/kg before anesthesia induction

Sponsors

The Third Affiliated Hospital Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 60 years or older but under 90 years, regardless of gender; 2.Patients scheduled for elective liver resection under general anesthesia; 3.American Society of Anesthesiologists (ASA) Class I to III; 4.Voluntary participation by the patient and their legal representative, with signed informed consent; 5.Patients who have not participated in other drug clinical trials within 3 months prior to screening;

Exclusion criteria

Exclusion criteria: 1.Patients with NYHA class = III, sick sinus syndrome, second-degree or higher AV block, or coagulation disorders; 2.Severe hepatic impairment (Child-Pugh C), severe renal impairment (requiring preoperative dialysis), or severe organic brain disease; 3.Patients with preoperative epilepsy, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, or myasthenia gravis; 4.Severe organ deficits (e.g., visual, auditory, or speech impairments) affecting preoperative visits and testing; 5.Preoperative Mini-Mental State Examination (MMSE) score < 18; 6.Contraindications to midazolam or remimazolam use; 7.Patients on long-term sedative medication or prolonged glucocorticoid therapy; 8.History of alcohol or substance dependence; 9.Other patients deemed ineligible by the investigator.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative delirium (POD) within 7 days after surgery;

Secondary

MeasureTime frame
MMSE scores at 1 day before surgery, 1 day, 3 days, and 7 days after surgery;Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at 1 day before surgery, immediately after surgery, and 1 day after surgery;Changes in blood pressure and heart rate during anesthesia induction and surgery;Anesthesia- and surgery-related times including anesthesia duration, surgery duration, emergence time, extubation time, and PACU stay duration;Anesthesia and intraoperative conditions including propofol dosage, anesthesia and surgical procedures, and drug types and dosages;Adverse events during and after surgery including intraoperative hypotension, hypertension, bradycardia, tachycardia, arrhythmias, hypoxemia, intraoperative awareness, postoperative nausea and vomiting, dizziness, headache, etc.;Total hospital length of stay and hospitalization costs after surgery;

Countries

China

Contacts

Public ContactChen Chaojin

The Third Affiliated Hospital Sun Yat-sen University

chenchj28@mail.sysu.edu.cn+86 13430322182

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026